2026-04-17T08:16:08Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1199202025-12-05T10:09:53Zcom_2072_1057col_2072_478917col_2072_478929
RECERCAT
author
Vinuesa Aumedes, Teresa
author
Herráez, Rocio
author
Oliver, Laura
author
Elizondo, Elisa
author
Acarregui, Argia
author
Esquisabel, Amaia
author
Pedraz, José Luis
author
Ventosa, Nora
author
Veciana, Jaume
author
Viñas, Miquel
2018-02-16T13:46:03Z2018-05-30T22:01:53Z2017-112018-02-16T13:46:03Z
This article describes the characterization of various encapsulated formulations of benznidazole, the current first-line drug for the treatment of Chagas disease. Given the adverse effects of benznidazole, safer formulations of this drug have a great interest. In fact, treatment of Chagas disease with benznidazole has to be discontinued in as much as 20% of cases due to side effects. Furthermore, modification of delivery and formulations could have potential effects on the emergence of drug resistance. The trypanocidal activity of new nanostructured formulations of benznidazole to eliminate Trypanosoma cruzi was studied in vitro as well as their toxicity in two cultured mammalian cell lines (HepG2 and Fibroblasts). Nanoparticles tested included nanostructured lipid carriers, solid lipid nanoparticles, liposomes, quatsomes, and cyclodextrins. The in vitro cytotoxicity of cyclodextrins-benznidazole complexes was significantly lower than that of free benznidazole, whereas their trypanocidal activity was not hampered. These results suggest that nanostructured particles may offer improved therapeutics for Chagas disease.
(c) American Society of Tropical Medicine and Hygiene, 2017 info:eu-repo/semantics/openAccess
Medicina tropical
Malaltia de Chagas
Medicaments
Nanomedicina
Tropical medicine
Chagas' disease
Drugs
Nanomedicine
Benznidazole nanoformulates: a chance to improve therapeutics for Chagas disease
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion